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Summary A cohort of 412 patients first attending a cystic fibrosis (CF) clinic between 1961 and 1989 were
followed up to 30 June 1989. The number of malignancies observed in the cohort was compared with the
number expected based on the age, sex and calendar-year-specific cancer registration rates for England and
Wales. Four CF patients were diagnosed as having malignancies before 30 June 1989. The tumours were:
adenocarcinoma of the terminal ileum; adenocarcinoma of the pancreas, testicular teratoma, and B-cell
lymphoma. This compares with 0.89 malignancies expected on the basis of rates in England and Wales
(Standardised Registration Ratio = 452; 95% confidence interval 122-1150, P = 0.03). The single case of
adenocarcinoma of the terminal ileum contrasts with less than 0.001 expected (P = 0.003) and that of the
pancreas with 0.007 expected (P = 0.01). A further adenocarcinoma of the pancreas was diagnosed 2 years
after the end of the study period. The two cases of pancreatic cancer compare with 0.008 expected
(P = 0.0001) during the period to mid 1991.
On the basis of the present findings and previous case reports in the literature adenocarcinoma of the
pancreas and adenocarcinoma of the terminal ileum may be associated with cystic fibrosis.
Cystic fibrosis (CF) is not usually considered to be associated
with malignancy. Until recently the expectation of life in
patients with CF was sufficiently short that cancer risk was
relatively unimportant. With the introduction of modern
treatment methods, however, survival of patients with CF
has increased appreciably. There have now been several case
reports of malignancy in patients with CF (Abdul-Karim et
al., 1982; Biggs et al., 1986; Cole & Pullen, 1970; Davis &
Sawicka, 1985; Gorvoy, 1981; Marra et al., 1990; McIntosh
et al., 1988; Miller, 1969; Redington et al., 1985; Roberts et
al., 1986; Siraganian et al., 1987; Stern et al., 1986; Swender
et al., 1982; Tedesco et al., 1986). Determining whether CF
patients are at greater risk of cancer is therefore becoming of
increasing relevance.
While case reports of CF and malignancy are suggestive of
a relationship, these do not allow the association between CF
and malignancy to be quantified. In order to assess this, we
have examined a cohort of patients with CF who attended
The Royal Brompton Hospital between 1961 and 1989. We
report here the results of analyses which compared cancer
incidence (and all-cause mortality) in the cohort with
national rates.
Patients and methods
The Royal Brompton Hospital is a national referral centre
for patients with CF and, since 1961, has had a special
interest in older patients with CF. Clinical details of all CF
patients first attending the Department of Cystic Fibrosis
between 1961 and 1989 were available from hospital records
and a computerised data base which is updated regularly. All
patients had a diagnosis of CF based on clinical features and
a raised sweat sodium (>70 mEq 1'). The majority of
patients are seen in outpatients at least every 3 months but
patients who are unwell are seen more frequently as neces-
sary. Once seen, patients are generally followed up for life,
sometimes in collaboration with a physician at a local hos-
pital. Clinical details of all CF patients under the care of The
Royal Brompton Hospital but admitted to other hospitals
are obtained by one of the CF clinical nurse specialists or the
person responsible for maintaining the computer database.
Person years at risk (pyar) by 5 year age group, sex and
calendar year were calculated from the date when the patient
was first seen at The Royal Brompton Hospital. Patients
ceased contributing pyar on 30th June 1989, or their date of
death, or the date last seen alive if either of these were
earlier. The number of cancer cases expected in the cohort on
the basis of national rates was obtained by multiplying the
age, sex, and calendar year-specific pyar by the cancer regi-
stration rates recorded for England and Wales in the same
age, sex and calendar years. National registration rates for
1971 were used to calculate expected cases before 1971, and
1984 rates used to derive expectations after 1984, since regi-
stration rates for these years were not available. A standard-
ised registration ratio (SRR) was calculated as the ratio of
the sum of observed to the sum of expected cases, multiplied
by 100. Cancer sites were coded to the International
Classification of Diseases (ICD), using the revision in force at
the time. (World Health Organisation, 1967; World Health
Organisation, 1977). Overall mortality in the cohort was
analysed in a similar way to give a standardised mortality
ratio (SMR), which compared observed deaths to age-, sex-,
and calendar year-specific expectations based on national
mortality rates. All analyses were performed using the PYRS
computer programme. (Coleman et al., 1986).
The statistical significance of SRRs and SMRs, and 95%
confidence intervals (CI), were obtained using the Poisson
distribution. All tests of significance were two-sided.
Results
Four patients developed a malignancy during the study
period. In addition, one patient was diagnosed as having
adenocarcinoma of the pancreas in July 1991. As this case
occurred after the period for which detailed follow-up on the
whole cohort was available, it was not included in the main
part of the analysis. An additional patient within the cohort
had a past history of tonsillar lymphoma successfully treated
by radiotherapy at age 11 (case not previously reported). His
lymphoma was not included in the calculations as the diag-
nosis had been made before he attended this hospital.
All of the patients developed their malignancy while under
routine follow-up and none of the patients was referred to
the hospital for specific diagnosis or management of a malig-
nancy.
Clinical cases
Patient I (Davis and Sawicka, 1985) A 23 year old woman
diagnosed as having CF at the age of 12 months, presented
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with vague right sided upper abdominal pain. There was no
nausea or vomiting and she described the pain as dull and
poorly localised with no relation to eating. Abdominal ult-
rasound showed a large gall bladder and atrophic pancreas
containing a bi-lobular mass in the head. Liver function tests
were normal, with no evidence of chronic liver disease. Nee-
dle aspiration of the pancreatic mass showed groups of
adenocarcinoma cells, confirmed histologically at post-
mortem 6 months later.
Patient 2 (Redington et al., 1985) A 29 year old man had
been diagnosed as having CF at the age of 6 months. He
developed diabetes mellitus aged 20 and had required admis-
sions for treatment of respiratory symptoms due to infection
with P. aeruginosa. Liver function tests had been abnormal
during the previous two years that he had been attending this
hospital and showed a normal bilirubin, markedly elevated
alkaline phosphatase (ten times normal) elevated yGT and
AST (both about three times normal). He was admitted with
a rapidly progressive illness with subcutaneous emphysema
and myonecrosis due to Clostridium septicum septicaemia.
Despite treatment he died within 12 h of admission. At post-
mortem an unsuspected moderately well differentiated
adenocarcinoma of the terminal ileum was found 1 cm from
the ileocaecal valve.
Patient 3 A 29 year old man, diagnosed as having CF at
age 2, was admitted with an exacerbation of respiratory
symptoms. He also reported loin pain, dysuria, frequency
and a painful swollen right testicle. The right testicle was
enlarged and tender; there was no lymphadenopathy or
hepatosplenomegaly. Initial haematological and biochemical
tests were normal. The serum a-fetoprotein was 15 Lg 1 '
(normal < 10 jig I'), serum P-HCG 27 iu 1` (nor-
mal<4iul-1) serum CEA 2tLgl-' (normal<IOtgl-'). A
right orchidectomy showed a teratoma with prominent vas-
cular invasion. Staging investigations showed no evidence of
metastatic disease. He was treated with bleomycin, vincristine
and cisplatin with no subsequent evidence of tumour recur-
rence. Sixteen months after the diagnosis of his teratoma he
was admitted with a terminal respiratory tract infection.
Post-mortem examination showed no evidence of residual
tumour.
Patient 4 A 63 year old man with CF was admitted with an
acute exacerbation of his respiratory symptoms. The diag-
nosis of CF had been made at the age of 50 when he
presented with a history of repeated respiratory tract infec-
tions and heat prostration in hot climates. He had an
elevated sweat sodium which did not suppress with fludrocor-
tisone. Investigations revealed an Hb of 10.9 g l` and WCC
of 17.3: the blood film showed occasional prolymphocytes.
The ESR was 40 mm hr-'. Bone marrow examination
showed normal appearances apart from reduced erythro-
poesis and lymphocytic infiltration; approximately 50% of all
nucleated cells were lymphocytes. Lymphocytic infiltration
compatible with B-cell lymphoma (chronic lymphocytic
leukaemia or CLL) was confirmed by cell markers. As he was
asymptomatic no treatment was given. He has remained in
reasonable health for 4 years apart from respiratory tract
infections.
Patient 5 (case occurring after the study period). A 58 year
old man had been diagnosed as having CF at the age of 21.
He was treated with pancreatic supplements and infrequent
courses of antibiotics for respiratory tract infections. He
developed right upper abdominal pain and an abdominal CT
scan showed changes suggestive of chronic pancreatitis and a
large pseudocyst. He1 subsequently deteriorated and
developed ascites, oedema and a periumbilical mass; biopsy
of the mass showed adenorcarcinoma. At post mortem 4
months later there was an 8 cm thick-walled pancreatic
pseudocyst, and an irregular 5 cm pancreatic adenocarcinoma
obstructing the gastro-oesophageal junction and common
bile duct.
Cohort analysis
Of the 413 patients seen, there was no follow-up on only one
patient. The analyses therefore relate to 412 patients (186
women and 226 men) with cystic fibrosis. These contributed
2708 pyar in total, the average follow-up period being 6.6
years. The majority of patients (315 or 76%) were aged
between 15 and 24 years when first seen; only 64 (16%) were
first seen at the Royal Brompton Hospital under age 15 and
33 (8%) over age 24. Fifty four (13%) of the patients were
first seen before 1971. Of these, the earliest were two patients
seen in 1961. A total of 203 deaths (91 in females, 112 in
males) were known to have occurred before 30th June 1989.
Of the remaining 209 patients, 184 were followed alive to the
end of the study period and 25 were lost to follow-up; seven
during 1988 or the first half of 1989 and 18 before then. Nine
deaths are known to have occurred after the end of the study
period and were not included in the mortality analyses.
The 203 deaths observed in the cohort was almost 100
times the 2.1 deaths expected on the basis of national rates
(SMR = 9670, 95% Cl 8382-11092). Mortality relative to
sex specific national rates was more than twice as high in
women (SMR= 16421, 95% Cl 13321-20314) as in men
(SMR = 7249, 95% Cl 5950-8695). The four cases of cancer
which occurred during follow-up to 30th June 1989 compare
with 0.89 malignancies expected on the basis of national rates
(SRR = 452, 95% Cl 122-1150, P = 0.03). The single case of
adenocarcinoma of the terminal ileum contrasts with less
than 0.001 expected cancers of the small intestine (ICD 8 and
9: 152) (SRR = 70537, P = 0.003) and that of the pancreas
with 0.007 expected cancers of the pancreas (ICD 8 and 9:
157) (SRR = 14379, P = 0.01).
In order to assess the statistical significance of the second
case ofpancreatic cancer, additional analyses were performed
assuming that all patients alive at the end of June 1989
survived to the end ofJuly 1991, except that the nine patients
known to have died during this period were censored at their
date of death. On these conservative assumptions, the two
cases of pancreatic cancer compare with 0.008 expected cases
(SRR = 24448, P = 0.0001).
Discussion
Malignancies occurring in cystic fibrosis are rare and we can
find only 19 cases reported in the literature; six cases of
leukaemia (Miller, 1969; Cole & Pullen, 1970; Biggs et al.,
1986), one case of Hodgkins disease (Marra et al., 1990),
four cases of adenocarcinoma of the terminal ileum (Roberts
et al., 1986; Siraganian et al., 1987; Swender et al., 1982;
Redington et al., 1985), two nephroblastomas (Wilms'
tumour) (Miller, 1969), three cases of adenocarcinoma of the
pancreas (Tedesco et al., 1986; Davis & Sawicka, 1985;
McIntosh et al., 1988), a case of retinoblastoma (Gorvoy,
1981) and two cholangiocarcinomas (Abdul-Karim et al.,
1982; Stern et al., 1986). While suggestive of a relationship
between CF and malignancy, these case reports do not allow
the strength of the association to be quantified. This study is
the first report of a cohort study of malignancy in patients
with CF.
The more than 4-fold excess of malignant tumours
observed in our cohort provides firmer evidence than
previously available for an association between CF and the
development of malignancy. This could be due to a direct
effect associated with the CF genetic defect or it may be due
to a secondary effect in an organ affected by the CF disease
process. It should be noted however, that patients included in
this study were all under follow up for CF and attended this
hospital regularly. As The Royal Brompton Hospital is a
tertiary referral hospital our cohort represents a relatively
selected population. None of the patients was referred to us
because of symptoms associated with the cancer: four of the
five cases were diagnosed more than 10 years after first
registration at the hospital and one case, two and a half years
after registration. As most patients are followed up for life,CYSTIC FIBROSIS AND MALIGNANCY 1027
malignancies in the patients are more likely to have been
detected than in the general population both because of the
high degree of clinical surveillance and because many have
undergone post mortem examination. In addition, national
cancer registration data are to some extent incomplete,
whereas we should know of all cancers diagnosed in the CF
patients.
The finding of two cases of pancreatic adenocarcinoma in
our patients is most remarkable. The second case occurred
after the end of the study period for which we have complete
follow up, and therefore the analysis including it needs to be
interpreted with caution. With the conservative assumption
that all patients (except those known to have died) survived
to the end of July 1991, the two cases represent a highly
significant excess (P = 0.0001). Pancreatic cancer is a rare
tumour in young adults. Two of the three previously
reported cases were in patients aged under 30, and one in a
patient aged 42. We would argue that the present findings,
taken together with the case reports in the literature, give
strong evidence for a real association between CF and
adenocarcinoma of the pancreas which is biologically plausi-
ble. Clinically significant pancreatic dysfunction is a feature
in about two thirds of patients with cystic fibrosis and may
be associated with atrophy of the pancreas and subsequently
fibrosis (Oppenheimer & Esterly, 1975).
Adenocarcinoma of the terminal ileum is a rare tumour
which has previously been reported in three patients with
cystic fibrosis from other CF centres (Roberts et al., 1986;
Siraganian et al., 1987; Swender et al., 1982). The single case
which occurred in our cohort was a highly significant finding
(P = 0.003). This case was previously unsuspected when diag-
nosed at post-mortem and therefore an appropriate com-
parison group is not available. Evidence for a real associa-
tion between this cancer and CF, based on the case reports in
the literature, is considered to be strong (Miller, 1988). The
failure of pancreatic enzyme secretion results in abnormal
small bowel contents and this is combined with abnormal
bile acid metabolism (Weizman et al., 1986), altered mucosal
enzymes (Morin et al., 1976) and impaired mucosal absorp-
tion (Fondacaro et al., 1982). Steatorrhoea in non-CF
patients has also been associated with adenocarcinoma or
lymphoma of the jejunum (Swinson et al., 1983).
These observations suggest that alteration in the functional
environment of the small bowel or pancreas may predispose
to the development of malignancy. A similar case for altera-
tion in the functional environment could be made for the
development of cholangiocarcinoma reported in two cases in
the literature (Abdul-Karim et al., 1982; Stern et al., 1986),
as bile acid metabolism is known to be abnormal in CF
(Morin et al., 1976). However despite the severe and wide-
spread damage to the lungs of most CF patients, there have
been no reported pulmonary tumours. Analysis of the CF
genotype of those patients with tumours would have been
very interesting but unfortunately this was not performed.
Most patients with CF have received large quantities of
antibiotics, pancreatic supplements, and vitamin prepara-
tions. None of these substances is known to be carcinogenic
but many antibiotics are secreted in the bile and alter its
composition.
The Standardised Mortality Ratio in women was found to
be more than twice as high as in men. The difference in
survival between sexes in early adult life has been reported in
studies from the United Kingdom before (British Paediatric
Association Working Party on Cystic Fibrosis, 1988), but not
in one study from the United States. The reasons for the
difference in survival are not clear.
The prognosis for patients with CF has improved con-
siderably over the past 30 years. Prolonged survival may
result in more patients developing malignancies. The risk of
malignancy is small in comparison to the very high overall
mortality due to respiratory failure but physicians should
nevertheless be aware of the possibility. Adenocarcinoma of
the pancreas and adenocarcinomas of the terminal ileum may
be associated with CF. Further follow-up data on adults with
CF are required to monitor the risks.
We would like to thank Miss Amelia Wise for keeping the CF
database, Mrs Fran Duncan-Skingle and Miss Fiona Foster, Clinical
Nurse Specialists in Cystic Fibrosis.
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